10-Q: Quanterix Q2 Loss Widens Amid Revenue Decline

Quanterix Corporation reported a significant increase in net loss for Q2 2025, driven by declining revenues and a $6.4 million goodwill impairment charge, while strategically acquiring Akoya Biosciences and implementing cost reductions.

Summary

• Total revenues decreased by 29% to $24.5 million for the three months ended June 30, 2025, compared to $34.4 million in the prior year period.
• Net loss significantly widened to $30.0 million for the three months ended June 30, 2025, up from $7.4 million for the same period in 2024.
• A goodwill impairment charge of $6.4 million was recorded during the second quarter of 2025 due to a larger than expected decline in revenue and bookings.
• The company completed the acquisition of Emission, Inc. on January 8, 2025, for $16.6 million in total consideration, including cash and contingent payments.
• Subsequent to the quarter, on July 8, 2025, the company completed the acquisition of Akoya Biosciences, Inc. for approximately 7.8 million shares of common stock and $19.6 million in cash, also settling Akoya's debt for $82.1 million.
• Restructuring plans were announced in May and July 2025, including reductions in force, expected to result in annualized savings of approximately $67.0 million, increasing to $85.0 million.
• The company expects to incur operating losses at least through the next 12 months but anticipates the combined company (with Akoya) to be cash flow breakeven in 2026.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in revenue and gross profit, a substantial increase in net loss, and a goodwill impairment charge. While strategic acquisitions and cost-cutting measures are underway, and a future cash flow breakeven is projected, the immediate financial performance and ongoing internal control weaknesses weigh heavily on the current outlook.

Positives

• Net cash used in operating activities decreased to $19.5 million for the six months ended June 30, 2025, an improvement from $25.1 million in the prior year period, driven by improved collections and decreased raw material purchases.
• The strategic acquisition of Emission, Inc. aims to secure highly controlled beads for next-generation platforms and expand into a new multi-plex market segment.
• The acquisition of Akoya Biosciences, Inc. is expected to establish a fully integrated technology ecosystem for biomarker identification across tissue and blood, expanding into oncology and immunology.
• Implementation of cost reduction plans in May and July 2025 are projected to yield significant annualized savings of approximately $85.0 million.
• The company received ISO 13485 certification for its Billerica, Massachusetts operations on January 31, 2025, indicating a robust quality management system for medical device manufacturing.
• The company anticipates achieving cash flow breakeven in 2026 for the combined entity, reflecting confidence in synergy realization.

Negatives

• Total revenues decreased by 29% for the three months ended June 30, 2025, and by 18% for the six months ended June 30, 2025, compared to the respective prior year periods.
• Product revenue declined by 15% in Q2 2025, primarily due to reduced demand from academic customers (slowdown in US federal research funding) and pharmaceutical customers (decreased R&D spending and clinical trials).
• Service and other revenue decreased by 48% in Q2 2025, mainly due to the completion of a collaboration agreement with Eli Lilly and Company and other large pharmaceutical projects not repeating.
• Net loss significantly increased to $30.0 million in Q2 2025 from $7.4 million in Q2 2024, and to $50.5 million for the six months ended June 30, 2025, from $18.6 million in the prior year period.
• A $6.4 million goodwill impairment charge was recorded in Q2 2025, reflecting a decline in the fair value of the reporting unit.
• Operating expenses increased by 46% in Q2 2025, largely due to the goodwill impairment and non-recurring acquisition-related costs.
• The company continues to report material weaknesses in internal control over financial reporting related to inventory valuation and Accelerator Revenue accounting, indicating ongoing control deficiencies.

Risks

• Rapidly changing macro-economic conditions, including reductions in US federal research funding, decreased research and development spending by larger pharmaceutical customers, and new import tariffs, could continue to negatively impact revenue and bookings.
• The company's ability to successfully integrate acquired companies, such as Emission, Inc. and Akoya Biosciences, Inc., and realize anticipated synergies and cost savings is subject to execution risks.
• Failure to remediate the identified material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information accurately.
• The uncertain macro-economic environment is expected to cause continued fluctuations in consumable sales and Accelerator Laboratory revenue.
• The company expects to incur operating losses for at least the next 12 months, and future capital requirements may necessitate raising additional capital, which could lead to stockholder dilution or unfavorable debt terms.

Future Outlook

The company expects to incur operating losses for at least the next 12 months, with expenses anticipated to increase due to expanded research and development efforts, investments in diagnostics initiatives, and strategic acquisitions. However, the acquisition of Akoya Biosciences and subsequent integration activities are projected to generate synergies, enabling the combined company to achieve cash flow breakeven in 2026. Softness in instrument sales is expected to continue in 2025 due to a constrained capital funding environment, but the introduction of the Simoa One instrument by the end of 2025 is expected to help grow sales in future years. The uncertain macro-economic environment is also expected to cause fluctuations in consumable sales and Accelerator Laboratory revenue for the remainder of 2025.

Management Comments

• The acquisition of Emission, Inc. is part of plans to secure the use of Emission's highly controlled beads in next-generation platforms and expand into a new multi-plex market segment targeting third-party original equipment manufacturer customers.
• The acquisition of Akoya Biosciences, Inc. is part of plans to establish the first fully integrated technology ecosystem to identify and measure biomarkers across tissue and blood, expand technology offerings into oncology and immunology, and expand the portfolio of laboratory service offerings.
• The company believes that continued investment in research and development is essential to its long-term competitive position and expects that the realization of anticipated synergies from the Akoya acquisition should enable maintenance of R&D expense at a more consistent level.
• The company expects the combined company (with Akoya) will be cash flow breakeven in 2026, driven by actions taken to reduce operating costs, preserve cash, and realize anticipated synergies.

Industry Context

The company operates in the life sciences industry, specializing in ultra-sensitive digital immunoassay platforms for research and diagnostics, particularly in neurology, oncology, and immunology. The recent acquisition of Akoya Biosciences expands its offerings into spatial biology, a rapidly evolving technology for tissue analysis and spatial phenotyping. The industry is currently facing headwinds from reduced US federal research funding and decreased R&D spending by larger pharmaceutical customers, impacting demand for instruments and services. Despite these challenges, the company's strategic acquisitions aim to broaden its technology ecosystem and market reach, positioning it for future growth in high-unmet medical need areas.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• Entered into agreements with two entities owned by selling shareholders of Emission, Inc. in Q1 2025 for development work on future products, incurring $0.3 million in operating expenses.
• Harvard University: A member of the company's Board of Directors receives a portion of payments from the Harvard License Agreement. Sales to Harvard and Mass General Brigham were not material.
• Tufts University: A member of the company's Board of Directors receives compensation from Tufts based on royalties and license payments made by the company. Royalty expenses related to the Tufts License Agreement were $0.4 million in Q2 2025 and $0.8 million for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Face potential dilution if additional capital is raised through equity offerings, and the significant net loss and goodwill impairment could negatively impact share price.
• Employees: Affected by reductions in force implemented in May and July 2025 as part of cost reduction and synergy realization plans.
• Customers: May experience fluctuations in service availability (e.g., Accelerator Laboratory revenue) due to macro-economic conditions, but also benefit from new product development (Simoa One) and expanded offerings through acquisitions (Akoya).
• Creditors: Akoya's debt financing arrangement with Midcap Financial Trust was settled for $82.1 million concurrently with the acquisition, impacting the company's cash position.

Next Steps

• Continue to expand research and development efforts to improve existing products and develop new assays and instruments.
• Invest further in Lucent Diagnostics, additional Laboratory Developed Tests (LDTs), and other diagnostics initiatives.
• Seek Premarket Approval (PMA), de novo classification, or 510(k) clearance from the FDA for existing or new products.
• Strategically acquire and integrate companies or technologies complementary to the business, including the ongoing integration of Akoya Biosciences, Inc.
• Make required earnout payments under the Emission, Inc. acquisition agreement upon completion of technical and performance milestones.
• Enter into collaboration arrangements or in-license other products and technologies.
• Add or enhance operational, financial, and management information systems.
• Continue efforts to remediate material weaknesses in internal control over financial reporting through fiscal year 2025.
• Launch the Simoa One instrument by the end of 2025 to help grow instrument sales.
• Implement additional cost savings over the remainder of 2025 to increase annualized savings to approximately $85.0 million.

Key Dates

Recommendation

The company's Q2 2025 results show significant deterioration in revenue and profitability, coupled with a goodwill impairment and ongoing material weaknesses in internal controls. This indicates substantial operational challenges. However, the strategic acquisitions of Emission and Akoya Biosciences, along with aggressive cost-cutting measures and a stated goal of cash flow breakeven in 2026, suggest a transformative period. For a seasoned investor, the current financial performance is a concern, but the long-term strategic positioning and potential for synergy realization offer a speculative upside. A 'hold' recommendation is appropriate to observe the execution of these strategic initiatives and the remediation of internal control issues before making a more definitive investment decision.

Keywords

Quanterix, QTRX, Life Sciences, Diagnostics, Immunoassay, Simoa, Spatial Biology, Akoya Biosciences, Emission Inc., Goodwill Impairment, Restructuring, Biomarkers, SEC Filing, Quarterly Report